Sugi Predict

Sugi Predict / Compounds / SCHEMBL2723366

SCHEMBL2723366

SCHEMBL2723366

CC(C)(C)OC(=O)NCCNc1nc(Cl)ncc1Br

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STK17B O94768 1/20 0.67
▸ STK17A Q9UEE5 1/20 0.67
▸ LATS1 O95835 1/20 0.46
▸ BCHE P06276 1/20 0.44
▸ BRD4 O60885 6/20 0.43
▸ SUV39H2 Q9H5I1 2/20 0.41
▸ MALT1 Q9UDY8 1/20 0.40
▸ CA12 O43570 3/20 0.39
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ CKS1B P61024 1/20 0.38
▸ SKP1 P63208 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ FPR3 P25089 1/20 0.38
▸ FPR2 P25090 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3868126 0.93 STK17B (0.79) STK17BSTK17ABRD4CA12CA1
SCHEMBL25949191 0.86 STK17B (0.50) STK17BSTK17ALATS1BCHEBRD4
SCHEMBL11909214 0.85 STK17B (0.67) STK17BSTK17ALATS1BCHEBRD4
SCHEMBL20154907 0.85 STK17B (0.49) STK17BSTK17ALATS1BCHEBRD4
SCHEMBL4549833 0.85 STK17B (0.67) STK17BSTK17ALATS1BCHEBRD4
SCHEMBL3873064 0.84 STK17B (0.53) STK17BSTK17ALATS1MEN1KMT2A
SCHEMBL29474436 0.82 STK17B (0.54) STK17BSTK17ALATS1CA12CA1
SCHEMBL2722686 0.82 STK17B (0.54) STK17BSTK17ALATS1CA12CA1
SCHEMBL1774178 0.82 GLP1R (0.45) STK17BSTK17ACA12CA9MEN1
SCHEMBL12968578 0.81 STK17A (0.62) STK17BSTK17ALATS1BCHEBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885LATS1 523/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885LATS1 523/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A STK17B 986/4885STK17A 957/4885LATS1 1115/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 STK17B 852/4885STK17A 1072/4885LATS1 2560/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 STK17B 1245/4885STK17A 1696/4885LATS1 1382/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885LATS1 523/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885LATS1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.